Authors | Signature | Number of casesa | Treatment | Context | Method | Platform |
---|---|---|---|---|---|---|
Jansen et al. [110] | 44 genes | 48 training set, 66 validation set | TAM | Recurrent breast cancer | Top-down (response vs. progression) | Microarray (local) |
Loi et al. [112] | Tamoxifen predictor (181 genes) | 99 training set, 69 validation set 87 validation set | TAM | Adjuvant treatment | Top-down (relapse vs. no relapse) | Microarray (Affymetrix, Santa Clara, CA, USA) |
Oh et al. [111] | Estrogen-regulated genes (822 genes) | Cell lines + 65 discovery set, 60 validation set (1) | Heterogeneous TAM (1) | Adjuvant treatment | Bottom-up (estrogen induced gene expression changes in MCF-7 cell lines) | Microarray (Agilent Technologies, Inc., Santa Clara, CA, USA) |
 |  | 90 validation set (2) | TAM +/- NAC (2) |  |  |  |
 |  | 250 validation set (3) | Heterogeneous (3) |  |  |  |
Symmans et al. [113] | SET index (165 genes) | 437 training set, 225 + 298 validation set (1) | Heterogeneous TAM (1) | Adjuvant treatment | Bottom-up (genes coexpressed with estrogen receptor) | Microarray (Affymetrix) |
 |  | 122 validation set (2) | NAC + TAM or Al (2) |  |  |  |
 |  | 208 + 133 validation set (3) | Non-treated (3) |  |  |  |